Anticoagulant

Edoxaban: Clinical Studies & Trial Evidence

Edoxaban is an anticoagulant that prevents blood clot formation and is used to treat or prevent deep vein thrombosis, pulmonary embolism, and atrial fibrillation.

Mechanism Interactions Evidence Clinical Studies

Grade AGrade A — Large RCTs for stroke prevention in AF, VTE treatment, and ACS management

Anticoagulants have transformed outcomes in AF stroke prevention and VTE therapy, with DOACs demonstrating non-inferiority or superiority to warfarin with improved safety profiles in landmark trials.

Key Clinical Trials

RE-LY — Randomized Evaluation of Long-Term Anticoagulation Therapy

2009

Population: 18,113 patients with AF at risk of stroke

Primary endpoint: Stroke or systemic embolism

Dabigatran 150mg superior to warfarin for stroke prevention (RR 0.66, p<0.001) with similar major bleeding. Dabigatran 110mg non-inferior with less bleeding. First DOAC trial in AF.

NEJM 2009; 361(12): 1139–1151

ROCKET AF — Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition

2011

Population: 14,264 patients with non-valvular AF

Primary endpoint: Stroke or non-CNS systemic embolism

Rivaroxaban non-inferior to warfarin for primary endpoint. Significant reduction in intracranial hemorrhage (0.5% vs 0.7%, p=0.02). Once-daily dosing advantage.

NEJM 2011; 365(10): 883–891

ARISTOTLE — Apixaban for Reduction in Stroke

2011

Population: 18,201 patients with AF

Primary endpoint: Stroke or systemic embolism

Apixaban superior to warfarin for stroke prevention (RR 0.79, p=0.01), with less major bleeding (RR 0.69, p<0.001) and lower mortality (RR 0.89, p=0.047). Often cited as best overall DOAC profile in AF.

NEJM 2011; 365(11): 981–992

EINSTEIN VTE — Rivaroxaban for Symptomatic VTE

2012

Population: 3,449 (DVT) + 4,832 (PE) patients

Primary endpoint: Recurrent symptomatic VTE

Rivaroxaban non-inferior to enoxaparin/VKA for VTE treatment. Significantly less major bleeding in PE study (1.1% vs 2.2%). Oral-only regimen without initial parenteral anticoagulation.

NEJM 2012; 366(14): 1287–1297 / 366(21): 1287

Numbers Needed to Treat (NNT / NNH)

AF stroke prevention: NNT ≈ 37 per year vs no anticoagulation (CHADS₂ score 2). DOAC vs warfarin: NNT ≈ 167 to prevent 1 additional stroke per year. VTE recurrence prevention: NNT ≈ 20 over 3 months. ICH reduction (DOACs vs warfarin): NNH avoided ≈ 200 per year.

Systematic Reviews & Meta-Analyses

•Ruff et al. (Lancet 2014) — Meta-analysis of 4 DOAC AF trials: DOACs reduce stroke by 19%, ICH by 52%, mortality by 10% vs warfarin
•Castellucci et al. (BMJ 2022) — DOACs vs LMWH for cancer-associated VTE: apixaban and rivaroxaban preferred
•Cochrane (2022) — Anticoagulants for AF: DOACs associated with better safety and comparable efficacy vs warfarin
•van der Hulle et al. (Blood 2014) — Efficacy and safety of DOACs vs VKA in VTE: overall NNT ≈ 40 for preventing recurrent VTE

Guideline Endorsements

✓ESC AF Guidelines 2020 — DOACs preferred over VKA for non-valvular AF (Class I, Level A)
✓ACC/AHA AF Guidelines 2023 — DOACs recommended for CHA₂DS₂-VASc ≥2 (men) / ≥3 (women)
✓NICE NG196 (2021) — Apixaban, dabigatran, edoxaban, rivaroxaban preferred over warfarin for AF
✓ISTH/ASH VTE Guidelines 2020 — DOACs preferred over VKA for first-line VTE treatment
✓ESC VTE Guidelines 2019 — DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) for acute PE/DVT

Comparative Effectiveness

↔DOACs vs warfarin in AF: DOACs superior/non-inferior for efficacy with better safety (less ICH); warfarin still preferred in mechanical heart valves
↔Apixaban vs rivaroxaban (AF): network meta-analyses suggest apixaban has best safety profile
↔Dabigatran vs rivaroxaban (VTE): comparable efficacy; dabigatran requires initial parenteral therapy
↔LMWH vs DOACs (cancer-VTE): DOAC (apixaban/rivaroxaban) now preferred in most cancer types (ADAM VTE, SELECT-D trials)

Key Safety Signals

All anticoagulants: bleeding risk (GI, intracranial, surgical). Warfarin: narrow therapeutic index, requires INR monitoring. DOACs: limited reversal options (idarucizumab for dabigatran, andexanet alfa for Xa inhibitors). Dabigatran: higher GI bleeding vs warfarin. Warfarin: high drug-drug and food interaction burden. Heparin: heparin-induced thrombocytopenia (HIT) — rare but life-threatening; use argatroban/danaparoid as alternative.

Evidence Limitations

!Major DOAC trials in AF predominantly enrolled moderate-risk patients — very high CHA₂DS₂-VASc evidence less robust
!Trials excluded patients with severe renal impairment (eGFR <25–30), limiting DOAC evidence in advanced CKD
!Cancer-VTE evidence has evolved rapidly — earlier LMWH-based recommendations now partially superseded by DOAC trials
!Head-to-head DOAC comparisons limited; most comparisons via network meta-analysis

Conditions Treated with Edoxaban

Atrial FibrillationHow used →Deep Vein Thrombosis (DVT)How used →Pulmonary EmbolismHow used →

Questions about Edoxaban?

Our AI Symptom Checker analyses your symptoms, suggests diagnoses, and identifies relevant medications — including clinical evidence summaries.

Use AI Symptom Checker →